Retour à la veille

CVE-2026-95777

Publié : 3 novembre 2026
Modifié : 3 novembre 2026
Lien officiel NVD
Score CVSS
3.1
LOW

Description détaillée

A sensitive information disclosure vulnerability exists in the management interface of HPE Networking Fabric Composer. Successful exploitation could allow a low-privileged attacker to obtain certain sensitive information stored on the affected system.

Vecteur d'attaque (CVSS)

Vecteur brut :CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N

Références et Patchs

Dernières Vulnérabilités

CVE-2026-95860

node-opcua is an OPC UA implementation for TypeScript and Node.js. From 2.42.0 until 2.180.0, namespace-level access control configured through setDefaultRolePermissions is not honored by the runtime enforcement path for nodes without explicit per-node RolePermissions. SessionContext.getApplicableRolePermissions reads a missing or null DefaultRolePermissions metadata value instead of the configured namespace field, and the null result is treated permissively. An anonymous network client can consequently write variables with CurrentWrite access or call bound methods when an operator configured a restrictive namespace default and relied on inheritance. Servers with no declared policy, nodes with explicit per-node permissions, and correctly bound programmatic namespace metadata are outside the authorization-bypass case. This issue is fixed in version 2.180.0.

VOIR DÉTAILS

CVE-2026-82161

Dell Wyse Management Suite, versions prior to 2609.0.0.155, contain an Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability. A low privileged attacker with remote access could potentially exploit this vulnerability, leading to Script injection.

VOIR DÉTAILS

CVE-2026-82160

Dell Wyse Management Suite, versions prior to 2609.0.0.155, contain an Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability. A low privileged attacker with local access could potentially exploit this vulnerability, leading to Script injection.

VOIR DÉTAILS